Renal Transplantation - An Experience of 500 Patients.

Journal Article (Journal Article)

Background

Renal transplantation is the treatment modality of choice for patients with end stage kidney failure. We present our experience of graft and patient survival of initial 500 renal transplants performed between May 1991 and July 2006, at Army Hospital (R&R).

Material and methods

All patients received triple drug immunosuppression with cyclosporine/tacrolimus, azathioprine/ mycophenolate mofetil and steroids. Patients in high risk group received induction therapy with IL-2 receptor blockers/anti-thymocyte globulin.

Results

Majority of the recipients (79%) were males, whereas majority of the donors (59.4%) were females. In the donor profile, 385 (77%) transplants were live related, 108 (21.6 %) were spousal and 7 (1.4%) were cadaveric transplants. Mean age of the donors and recipients was 42.11 ± 11.53 years (range 19-72 years) and 33 ± 9.39 years (range 5-60 years) respectively. Eighty two patients (16.4%) were lost to follow up and the present data on rejections, patients and graft survival pertains to 418 patients. These patients have been followed up for a mean period of 2.63 years (SE, 0.122; median 1.8 years; range 0-13.36 years). Acute rejection episodes occurred in 115 (27.3%) patients and 95% of these could be reversed with steroids/ATG. Sixty eight patients (16%) have died on follow-up. Our one-year, 5 year and 10 year estimated graft survival is 95.4% (SE, 0.01), 80.5% (SE, 0.03) and 53.1% (SE, 0.09) respectively and patient survival at one year is 93.2% (SE, 0.01). The estimated graft and patient survival in our series is 9.83 (95% CI, 8.92-10.73) and 9.80 (8.93-10.67) years respectively.

Conclusion

This centre's short-term graft survival of 95.4% is comparable to the best centres of the world.

Full Text

Duke Authors

Cited Authors

  • Varma, PP; Hooda, AK; Sinha, T; Chopra, GS; Karan, SC; Sethi, GS; Badwal, S; Kotwal, A

Published Date

  • April 2007

Published In

Volume / Issue

  • 63 / 2

Start / End Page

  • 107 - 111

PubMed ID

  • 27407961

Pubmed Central ID

  • PMC4925376

Electronic International Standard Serial Number (EISSN)

  • 2213-4743

International Standard Serial Number (ISSN)

  • 0377-1237

Digital Object Identifier (DOI)

  • 10.1016/s0377-1237(07)80049-9

Language

  • eng